Sotwe logo Sotwe logo

Top Tweets for #CAPItello281

urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
0
5
2
0
855
OncBrothers's profile image
Oncology Brothers Verified account @OncBrothers
We touched on 6 studies (3 from #ASCO26 and 3 recent @FDAOncology ✅) during our GU Malignancies Conference Highlights w/ @Uromigos ⭐️ #PROTEUS ⭐️ #TALAPRO3 ⭐️ #EV302 ✅ #POTOMAC ✅ #CAPItello281 ✅ #LITESPARK022 #OncTwitter #gusm @OncUpdates
OncBrothers's tweet photo. We touched on 6 studies (3 from #ASCO26 and 3 recent @FDAOncology ✅) during our GU Malignancies Conference Highlights w/ @Uromigos ⭐️ #PROTEUS ⭐️ #TALAPRO3 ⭐️ #EV302 ✅ #POTOMAC ✅ #CAPItello281 ✅ #LITESPARK022 #OncTwitter #gusm @OncUpdates https://t.co/GauWDPkcw3
OncBrothers's profile image
Oncology Brothers Verified account @OncBrothers
GU Malignancies Conference Highlights from #ASCO26 (and recent @US_FDA ✅) w/ @Uromigos ⭐️ #PROTEUS ⭐️ #TALAPRO3 ⭐️ #EV302 ✅ #POTOMAC ✅ #CAPItello281 ✅ #LITESPARK022 Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ https://t.co/DOo4V61t61 #OncTwitter @OncUpdates
2
29
9
4
8K
2
43
29
14
9K
OncBrothers's profile image
Oncology Brothers Verified account @OncBrothers
GU Malignancies Conference Highlights from #ASCO26 (and recent @US_FDA ✅) w/ @Uromigos ⭐️ #PROTEUS ⭐️ #TALAPRO3 ⭐️ #EV302 ✅ #POTOMAC ✅ #CAPItello281 ✅ #LITESPARK022 Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ https://t.co/DOo4V61t61 #OncTwitter @OncUpdates
2
29
9
4
8K
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
0
3
1
0
667
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
1
5
4
0
808
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
2
7
3
1
727
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
1
7
3
1
630
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
0
2
3
0
278
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
0
2
1
1
593
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
0
4
3
0
523
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
1
3
2
1
484
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
2
4
3
1
735
urotoday's profile image
UroToday.com Verified account @urotoday
Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
0
11
5
6
1K
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
0
13
3
1
1K
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
0
4
2
1
555
urotoday's profile image
UroToday.com Verified account @urotoday
Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
1
20
6
10
3K
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
1
6
2
3
742
urotoday's profile image
UroToday.com Verified account @urotoday
Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
0
2
2
2
834
urotoday's profile image
UroToday.com Verified account @urotoday
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
urotoday's tweet photo. Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
1
6
4
2
950
MikeSerzanMD's profile image
Michael Serzan, MD @MikeSerzanMD
💫PCa: Tx Selection, Response, & Monitoring #GU26 👉Dr @Daniel_J_George presents PRO from #CAPITELLO281 comparing #Capivasertib + Abi vs Abi alone in pts with PTEN-deficient mCSPC. 📊 No differences in least mean square change in FACT-P, physical well being, or functional well being ⚠️ However, #Capivasertib + Abi a/w☝️AEs leading to dose reductions/interruptions - Diarrhea (51% vs 8%) - Rash (35% vs 7%) - Hyperglycemia (38% vs 13%) 🔑 Key Takeaways that increased benefits of #Capivasertib must be weighed against early and reversible toxicity. Question if PROs measures are capturing effect of increased tox on QOL. @TDorffOnc @APCCC_Lugano @neerajaiims @bergsa83 @PBarataMD @Dr_RaviMadan @AarmstrongDuke @ChrisSweens1 @DrRanaMcKay @DrKarineTawagi @DrYukselUrun @yekeduz_emre @OncoAlert @urotoday @OncBrothers
MikeSerzanMD's tweet photo. 💫PCa: Tx Selection, Response, & Monitoring #GU26 👉Dr @Daniel_J_George presents PRO from #CAPITELLO281 comparing #Capivasertib + Abi vs Abi alone in pts with PTEN-deficient mCSPC. 📊 No differences in least mean square change in FACT-P, physical well being, or functional well being ⚠️ However, #Capivasertib + Abi a/w☝️AEs leading to dose reductions/interruptions - Diarrhea (51% vs 8%) - Rash (35% vs 7%) - Hyperglycemia (38% vs 13%) 🔑 Key Takeaways that increased benefits of #Capivasertib must be weighed against early and reversible toxicity. Question if PROs measures are capturing effect of increased tox on QOL. @TDorffOnc @APCCC_Lugano @neerajaiims @bergsa83 @PBarataMD @Dr_RaviMadan @AarmstrongDuke @ChrisSweens1 @DrRanaMcKay @DrKarineTawagi @DrYukselUrun @yekeduz_emre @OncoAlert @urotoday @OncBrothers
1
16
11
1
812

Last Seen Hashtags on Sotwe

wariaindonesia
Seen from Indonesia
jennifergranda
mommyincest
Femdom
Seen from Germany
ချောင်းရိုက်
pinoyscandal
Seen from Canada
momsonincest
ชายแท้รับงานกทม
Seen from Thailand
MaryTachibana
Seen from Malaysia
Voyeur

Trends for you

1
#BETAwards
Under 10K tweets
2
#ForbiddenDoor
Under 10K tweets
3
#HOTD
Under 10K tweets
4
Megan
Under 10K tweets
5
Melanie
Under 10K tweets
6
Yankees
Under 10K tweets
7
Druski
Under 10K tweets
8
D’Angelo
Under 10K tweets
9
Sonny Gray
Under 10K tweets
10
#NXTGAB
Under 10K tweets

Most Popular Users

elonmusk's profile image
1
Elon Musk Verified account
@elonmusk
240.6M followers
barackobama's profile image
2
Barack Obama Verified account
@barackobama
119.2M followers
realdonaldtrump's profile image
3
Donald J. Trump Verified account
@realdonaldtrump
111.7M followers
cristiano's profile image
4
Cristiano Ronaldo Verified account
@cristiano
110.5M followers
narendramodi's profile image
5
Narendra Modi Verified account
@narendramodi
107M followers
rihanna's profile image
6
Rihanna Verified account
@rihanna
97.6M followers
nasa's profile image
7
NASA Verified account
@nasa
92.2M followers
justinbieber's profile image
8
Justin Bieber Verified account
@justinbieber
90.9M followers
katyperry's profile image
9
KATY PERRY Verified account
@katyperry
87.6M followers
taylorswift13's profile image
10
Taylor Swift Verified account
@taylorswift13
81.4M followers
ladygaga's profile image
11
Lady Gaga Verified account
@ladygaga
73M followers
imvkohli's profile image
12
Virat Kohli Verified account
@imvkohli
69.8M followers
kimkardashian's profile image
13
Kim Kardashian Verified account
@kimkardashian
69.8M followers
youtube's profile image
14
YouTube Verified account
@youtube
68.7M followers
billgates's profile image
15
Bill Gates Verified account
@billgates
63.9M followers
neymarjr's profile image
16
Neymar Jr Verified account
@neymarjr
62.5M followers
theellenshow's profile image
17
The Ellen Show
@theellenshow
62.4M followers
cnn's profile image
18
CNN Verified account
@cnn
61.9M followers
x's profile image
19
X Verified account
@x
60.8M followers
selenagomez's profile image
20
Selena Gomez Verified account
@selenagomez
60.7M followers